Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

Damiano Rondelli, Giovanni Barosi, Andrea Bacigalupo, Josef T. Prchal, Uday Popat, Emilio P. Alessandrino, Jerry L. Spivak, B. Douglas Smith, Hans G. Klingemann, Steven Fruchtman, Ronald Hoffman

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) regimen. The patients received an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-matched related (n = 18) or unrelated (n = 2), or 1 Ag-mismatched related (n = 1), donors. RIC regimens included fludarabine/total body irradiation 200 cGy (n = 5) or 450 cGy (n = 1), fludarabine/melphalan (n = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarabine (n = 1). At the time of transplantation, all of the patients were at intermediate (n = 13) or high (n = 8) risk, according to the Dupriez classification. Of the patients, 19 had grade III or IV marrow fibrosis. All of the patients achieved full engraftment but one. Posttransplantation chimerism analysis showed more than 95% donor cells in 18 patients, while 2 patients achieved complete donor chimerism after donor leukocyte infusion (DLI). Acute graft-versus-host disease (GVHD) grades II to IV was observed in 7 patients, grades III to IV in 2, and extensive chronic GVHD in 8 of 18 evaluable patients. There were 3 patients who died from acute GVHD, infection, and relapse. There are 18 patients alive 12 to 122 months (median, 31 months) after transplantation, and 17 are in remission (1 after a second transplantation). The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high-risk MMM patients.

Original languageEnglish
Pages (from-to)4115-4119
Number of pages5
JournalBlood
Volume105
Issue number10
DOIs
Publication statusPublished - May 15 2005

Fingerprint

Primary Myelofibrosis
Hematopoietic Stem Cell Transplantation
Stem cells
Grafts
Thiotepa
Transplants
Melphalan
Cyclophosphamide
Graft vs Host Disease
Blood
Tissue Donors
Irradiation
Chimerism
Transplantation
fludarabine
Bone Marrow
Whole-Body Irradiation
Stem Cell Transplantation
Leukocytes
Fibrosis

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. / Rondelli, Damiano; Barosi, Giovanni; Bacigalupo, Andrea; Prchal, Josef T.; Popat, Uday; Alessandrino, Emilio P.; Spivak, Jerry L.; Douglas Smith, B.; Klingemann, Hans G.; Fruchtman, Steven; Hoffman, Ronald.

In: Blood, Vol. 105, No. 10, 15.05.2005, p. 4115-4119.

Research output: Contribution to journalArticle

Rondelli, D, Barosi, G, Bacigalupo, A, Prchal, JT, Popat, U, Alessandrino, EP, Spivak, JL, Douglas Smith, B, Klingemann, HG, Fruchtman, S & Hoffman, R 2005, 'Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia', Blood, vol. 105, no. 10, pp. 4115-4119. https://doi.org/10.1182/blood-2004-11-4299
Rondelli, Damiano ; Barosi, Giovanni ; Bacigalupo, Andrea ; Prchal, Josef T. ; Popat, Uday ; Alessandrino, Emilio P. ; Spivak, Jerry L. ; Douglas Smith, B. ; Klingemann, Hans G. ; Fruchtman, Steven ; Hoffman, Ronald. / Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. In: Blood. 2005 ; Vol. 105, No. 10. pp. 4115-4119.
@article{0b15911dfe5b4f05bea23e30d271c24a,
title = "Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia",
abstract = "A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) regimen. The patients received an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-matched related (n = 18) or unrelated (n = 2), or 1 Ag-mismatched related (n = 1), donors. RIC regimens included fludarabine/total body irradiation 200 cGy (n = 5) or 450 cGy (n = 1), fludarabine/melphalan (n = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarabine (n = 1). At the time of transplantation, all of the patients were at intermediate (n = 13) or high (n = 8) risk, according to the Dupriez classification. Of the patients, 19 had grade III or IV marrow fibrosis. All of the patients achieved full engraftment but one. Posttransplantation chimerism analysis showed more than 95{\%} donor cells in 18 patients, while 2 patients achieved complete donor chimerism after donor leukocyte infusion (DLI). Acute graft-versus-host disease (GVHD) grades II to IV was observed in 7 patients, grades III to IV in 2, and extensive chronic GVHD in 8 of 18 evaluable patients. There were 3 patients who died from acute GVHD, infection, and relapse. There are 18 patients alive 12 to 122 months (median, 31 months) after transplantation, and 17 are in remission (1 after a second transplantation). The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high-risk MMM patients.",
author = "Damiano Rondelli and Giovanni Barosi and Andrea Bacigalupo and Prchal, {Josef T.} and Uday Popat and Alessandrino, {Emilio P.} and Spivak, {Jerry L.} and {Douglas Smith}, B. and Klingemann, {Hans G.} and Steven Fruchtman and Ronald Hoffman",
year = "2005",
month = "5",
day = "15",
doi = "10.1182/blood-2004-11-4299",
language = "English",
volume = "105",
pages = "4115--4119",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

AU - Rondelli, Damiano

AU - Barosi, Giovanni

AU - Bacigalupo, Andrea

AU - Prchal, Josef T.

AU - Popat, Uday

AU - Alessandrino, Emilio P.

AU - Spivak, Jerry L.

AU - Douglas Smith, B.

AU - Klingemann, Hans G.

AU - Fruchtman, Steven

AU - Hoffman, Ronald

PY - 2005/5/15

Y1 - 2005/5/15

N2 - A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) regimen. The patients received an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-matched related (n = 18) or unrelated (n = 2), or 1 Ag-mismatched related (n = 1), donors. RIC regimens included fludarabine/total body irradiation 200 cGy (n = 5) or 450 cGy (n = 1), fludarabine/melphalan (n = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarabine (n = 1). At the time of transplantation, all of the patients were at intermediate (n = 13) or high (n = 8) risk, according to the Dupriez classification. Of the patients, 19 had grade III or IV marrow fibrosis. All of the patients achieved full engraftment but one. Posttransplantation chimerism analysis showed more than 95% donor cells in 18 patients, while 2 patients achieved complete donor chimerism after donor leukocyte infusion (DLI). Acute graft-versus-host disease (GVHD) grades II to IV was observed in 7 patients, grades III to IV in 2, and extensive chronic GVHD in 8 of 18 evaluable patients. There were 3 patients who died from acute GVHD, infection, and relapse. There are 18 patients alive 12 to 122 months (median, 31 months) after transplantation, and 17 are in remission (1 after a second transplantation). The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high-risk MMM patients.

AB - A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) regimen. The patients received an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-matched related (n = 18) or unrelated (n = 2), or 1 Ag-mismatched related (n = 1), donors. RIC regimens included fludarabine/total body irradiation 200 cGy (n = 5) or 450 cGy (n = 1), fludarabine/melphalan (n = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarabine (n = 1). At the time of transplantation, all of the patients were at intermediate (n = 13) or high (n = 8) risk, according to the Dupriez classification. Of the patients, 19 had grade III or IV marrow fibrosis. All of the patients achieved full engraftment but one. Posttransplantation chimerism analysis showed more than 95% donor cells in 18 patients, while 2 patients achieved complete donor chimerism after donor leukocyte infusion (DLI). Acute graft-versus-host disease (GVHD) grades II to IV was observed in 7 patients, grades III to IV in 2, and extensive chronic GVHD in 8 of 18 evaluable patients. There were 3 patients who died from acute GVHD, infection, and relapse. There are 18 patients alive 12 to 122 months (median, 31 months) after transplantation, and 17 are in remission (1 after a second transplantation). The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high-risk MMM patients.

UR - http://www.scopus.com/inward/record.url?scp=20844457922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844457922&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-11-4299

DO - 10.1182/blood-2004-11-4299

M3 - Article

C2 - 15671439

AN - SCOPUS:20844457922

VL - 105

SP - 4115

EP - 4119

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -